Australian Medical Equipment Stock News

Region Group (ASX:RGN) has completed its previously announced on market share buyback, repurchasing 14,100,000 shares for A$33.1 million, and extended the program’s duration through April 2, 2027, underscoring ongoing capital management efforts. See our latest analysis for Region Group. At a latest share price of A$2.23, Region Group’s recent 1-day and 7-day share price returns in positive territory contrast with weaker 90 day and year to date share price returns. The 1 year total shareholder...

Despite posting some strong earnings, the market for Resolute Mining Limited's ( ASX:RSG ) stock hasn't moved much. We...

Insiders who bought AU$284.9k worth of TZ Limited ( ASX:TZL ) stock in the last year have seen some of their losses...

The Australian market is experiencing a dip, influenced by geopolitical tensions and supply disruptions, causing investors to adopt a cautious stance. In such uncertain times, identifying stocks with potential resilience and growth becomes crucial. Penny stocks—though often seen as relics of past markets—can still offer intriguing opportunities when backed by solid financial health, especially in sectors poised for long-term success.

While Beetaloo Energy Australia Limited ( ASX:BTL ) shareholders have enjoyed a good week with stock up 20%, they need...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Excelsior...

As the Australian market navigates a challenging landscape marked by geopolitical tensions and natural disruptions, investors are keenly observing the impact on local indices, with a notable downturn expected at the open. In such uncertain times, dividend stocks often attract attention for their potential to provide steady income streams despite market volatility.

The Australian market is experiencing a turbulent phase, with shares poised for a decline amid geopolitical tensions and natural disruptions affecting key sectors. In such uncertain times, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, potentially offering resilience and long-term potential amidst market volatility.

The Australian market is experiencing a challenging period, with shares poised for a decline amid geopolitical tensions and natural disruptions, such as the impact of Tropical Cyclone Narelle on energy operations. In this environment, identifying high growth tech stocks requires a focus on companies with resilient business models and innovative capabilities that can navigate volatility and capitalize on emerging opportunities.

As the Australian market faces a challenging period marked by geopolitical tensions and natural disruptions, investors are keenly observing how these factors impact stock valuations. In such an environment, identifying stocks that may be trading below their estimated value can present opportunities for those looking to navigate the current volatility with strategic investments.

As the Australian market navigates a challenging period marked by geopolitical tensions and natural disruptions, such as Tropical Cyclone Narelle impacting key sectors like energy, investors are keenly observing how these dynamics influence small-cap stocks on the ASX. In this environment, identifying promising opportunities involves looking for companies that demonstrate resilience and potential for growth despite broader market uncertainties.

The Australian market is experiencing a challenging period, with shares set to drop amid geopolitical tensions and natural disruptions. Despite these hurdles, penny stocks continue to attract attention due to their potential for growth and value. Although the term "penny stocks" may seem outdated, these smaller or newer companies can offer unique opportunities when backed by strong financials.

Vulcan Energy Resources (ASX:VUL) has come into focus after releasing its full year 2025 earnings, reporting sales of €7.35 million and a net loss of €69.58 million, along with higher basic and diluted loss per share. See our latest analysis for Vulcan Energy Resources. The earnings release appears to have sharpened attention on risk, with the share price at A$3.27 posting a 3.48% 1 day gain and 9.36% 7 day share price return. However, it is still showing a 12.57% 30 day and 25.68% year to...

Why WHSP Holdings (ASX:SOL) just moved onto more investor watchlists WHSP Holdings (ASX:SOL) has drawn fresh attention after releasing half year results to January 31, 2026, reporting sales of A$620 million and net income of A$2,303 million compared with the prior period. Basic earnings per share from continuing operations were A$6.326 for the half year, while diluted earnings per share were A$6.289, both presented against lower figures reported a year earlier. See our latest analysis for...

EQ Resources (ASX:EQR) has completed a A$34 million follow on equity offering at A$0.05 per share, adding 680,000,000 new ordinary shares. This move directly affects valuation and ownership dilution. See our latest analysis for EQ Resources. The follow on equity offering comes after a period of very strong momentum, with a 30 day share price return of 31.25% and a 90 day share price return of 288.89%. The 1 year total shareholder return is also very large, suggesting sentiment has been...

Potential Great Western Exploration Limited ( ASX:GTE ) shareholders may wish to note that the Non-Executive Director...

Anyone interested in Chrysos Corporation Limited ( ASX:C79 ) should probably be aware that the Founder & Non-Executive...

Syrah Resources (ASX:SYR) has put out a busy update, pairing its full year 2025 earnings, which show sales of US$33.38 million and a net loss of US$100.66 million, with a A$104 million rights offering. See our latest analysis for Syrah Resources. The A$0.125 share price reflects a sharp reset in expectations, with a 30 day share price return of 47.92% and a 1 year total shareholder return of 47.41% loss, underscoring fading momentum despite the earnings update and capital raise. If this kind...

Why Lynas Rare Earths is on investors’ radar Lynas Rare Earths (ASX:LYC) has drawn attention after a strong period for its share price, with total return over the past year and past 3 months well ahead of its shorter term moves. For investors, the recent performance raises questions about how the current A$20.08 share price lines up with Lynas Rare Earths’ A$715.89 million in revenue, A$82.35 million in net income and its A$20.21b market value. See our latest analysis for Lynas Rare...

In March 2026, 4DMedical Limited completed a follow-on equity offering of A$83.00 million, issuing 14,067,797 new ordinary shares at A$5.90 each, reflecting a A$0.236 per-share discount in a subsequent direct listing. This sizeable capital raise signals management’s commitment to bolstering the balance sheet and funding growth initiatives, while also diluting existing shareholders’ ownership stakes. We’ll now explore how this A$83.00 million equity raise may reshape 4DMedical’s investment...

Why Brightstar Resources (ASX:BTR) Is Back On Investors’ Radar Brightstar Resources (ASX:BTR) has drawn fresh attention after analysts cut earnings and revenue forecasts for 2026, now expecting a loss, even as projections still point to strong revenue growth versus sector peers. See our latest analysis for Brightstar Resources. Brightstar’s 7 day share price return of 4.41% comes after a recent A$175m follow on equity offering and analyst forecast downgrades. However, the 30 day share price...

Life360 share performance sets context for recent moves Life360 (ASX:360) has drawn fresh attention after recent share price volatility, with the stock showing a 1.6% gain on the day and a 6.7% rise over the past week, despite weaker returns over the past month and past three months. See our latest analysis for Life360. The recent 6.7% 7-day share price return comes after a much weaker stretch. The 30-day share price return of 16.4% and year-to-date share price return of 40.6% indicate fading...

In March 2026, Telix Pharmaceuticals resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara, 18F-FET), an investigational PET imaging agent for distinguishing recurrent or progressive glioma from treatment effects in adult and pediatric patients, incorporating additional data and analysis requested after a prior Complete Response Letter. The filing is significant because TLX101-Px holds both Orphan Drug and Fast Track designations and could become the first FDA-approved...

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...